A phase II study of intravenous exatecan administered daily for 5 days, every 3 weeks to patients with biliary tract cancers

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 28, Issue 4, 2005, Pages 334-339

  Abou Alfa, Ghassan K ^a   Rowinsky, Eric K ^b   Patt, Yehuda Z ^c   Schwartz, Gary K ^a   Kelsen, David P ^a   Sharma, Sunil ^a   Siegel, Eve ^a   Becerra, Carlos R ^d   Eckhardt, S Gail ^e   Feit, Kevie ^f   De Jager, Robert ^f   O'Reilly, Eileen M ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b Cancer Treatment and Research Center   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^e UNIVERSITY OF COLORADO   (United States)

^f Daiichi Pharmaceutical Corporation   (United States)

Author keywords

Biliary tract cancers; Cholangiocarcinoma; DX 8951f; Exatecan; Gallbladder carcinoma; Phase II; Topoisomerase 1 inhibitor

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CAPECITABINE; EXATECAN; FLUOROURACIL; FOLINIC ACID; GEMCITABINE;

ABDOMINAL PAIN; ADULT; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BILE DUCT CARCINOMA; BILIARY TRACT CANCER; BONE MARROW SUPPRESSION; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; FATIGUE; FEMALE; FEVER; GALLBLADDER CANCER; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LIVER FUNCTION; MALE; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; AREA UNDER CURVE; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CAMPTOTHECIN; CHOLANGIOCARCINOMA; DNA TOPOISOMERASES, TYPE I; DRUG ADMINISTRATION SCHEDULE; FEMALE; GALLBLADDER NEOPLASMS; HALF-LIFE; HUMANS; MALE; MIDDLE AGED; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 23244444093     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.coc.0000158829.63542.2c     Document Type: Article

References (22)

1. Patel T. Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology. 2001;33:1353-1357.
2. Jemal A, Tiwari RC, Murray T, et al. American Cancer Society. Cancer statistics, 2004. Ca Cancer J Clin. 2004;54:8-29.
3. Falkson G, MacIntyre JM, Moertel CG. Eastern Cooperative Oncology Group experience with chemotherapy for inoperable gallbladder and bile duct cancer. Cancer. 1984;54:965-969.
4. Sanz-Altamira PM, O'Reilly E, Stuart KE, et al. A phase II trial of irinotecan (CPT-11) for unresectable biliary tree carcinoma. Ann Oncol. 2001;12:501-504.
5. Raderer M, Hejna MH, Valencak JB, et al. Two consecutive phase II studies of 5-fluorouracil/leucovorin/mitomycin C and of gemcitabine in patients with advanced biliary cancer. Oncology. 1999;56:177-180.
6. Gallardo JO, Rubio B, Fodor M, et al. A phase II study of gemcitabine in gallbladder carcinoma. Ann Oncol. 2001;12:1403-1406.
7. Kubicka S, Rudolph KL, Tietze MK, et al. Phase II study of systemic gemcitabine chemotherapy for advanced unresectable hepatobiliary carcinomas. Hepatogastroenterology. 2001;48:783-789.
8. Ellis PA, Norman A, Hill A, et al. Epirubicin, cisplatin and infusional 5-fluorouracil (5-FU) (ECF) in hepatobiliary tumours. Eur J Cancer. 1995;31A:1594-1598.
9. Ducreux M, Rougier P, Fandi A, et al. Effective treatment of advanced biliary tract carcinoma using 5-fluorouracil continuous infusion with cisplatin. Ann Oncol. 1998;9:653-656.
10. Malik IA, Aziz Z, Zaidi SH, et al. Gemcitabine and cisplatin is a highly effective combination chemotherapy in patients with advanced cancer of the gallbladder. Am J Clin Oncol. 2003;26:174-177.
11. Baluch S, Lau J, Dhillon T, et al. A well tolerated and highly effective regimen for locally advanced and metastatic biliary tract cancers with gemcitabine and cisplatin [abstract 1473]. Proc Am Soc Clin Oncol. 2003;22:367.
12. André T, Tournigand C, Rosmorduc O, et al. Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study. Ann Oncol. 2004;15:1339-1343.
13. Kumazawa E, Tohgo A. Antitumor activity of DX-8951f: a new camptothecin derivative. Exp Opin Invest Drugs. 1998;7:625-632.
14. Mitsui I, Kumazawa E, Hirota Y, et al. A new water-soluble camptothecin derivative, DX-8951f, exhibits potent antitumor activity against human tumors in vitro and in vivo. Jap J Cancer Res. 1995;86:776-782.
15. De Jager R, Cheverton P, Tamanoi K, et al. DX-8951f: summary of phase I clinical trials. Ann N Y Acad Sci. 2000;922:260-273.
16. Simon R. Optimal two-stage designs for phase II clinical trials. Controlled Clin Trials. 1989;10:1-10.
17. National Cancer Institute (NCI) common toxicity criteria (CTC). Version 2.0. January 30, 1998.
18. Green S, Weiss GR. Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria. Invest New Drugs. 1992;10:239-253.
19. Collins DG, Forrest A. IT2S user's guide. Buffalo, NY: State University of New York; 1995.
20. Rowinsky EK, Johnson TR, Geyer CE Jr, et al. DX-8951f, a hexacyclic camptothecin analog, on a daily-times-five schedule: a phase I and pharmacokinetic study in patients with advanced solid malignancies. J Clin Oncol. 2000;18:3151-3163.
21. Cantore M, Rabbi C, Guadagni S, et al. Intra-arterial hepatic chemotherapy combined with continuous infusion of 5-fluorouracil in patients with metastatic cholangiocarcinoma. Ann Oncol. 2002;13:1687-1688.
22. D'Adamo D, Hammond L, Donehower R, et al. Final results of a phase II study of DX-8951f (exatecan mesylate, DX) in advanced pancreatic cancer [abstract 532]. Proc Am Soc Clin Oncol. 2001:21.